查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1941132

HIV相關脂肪萎縮市場－全球產業規模、佔有率、趨勢、機會及預測（按類型、給藥途徑、分銷管道、地區和競爭格局分類，2021-2031年）

HIV-associated Lipodystrophy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Route of Administration, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球 HIV 相關脂肪代謝障礙市場預計將從 2025 年的 1.8582 億美元成長到 2031 年的 2.2862 億美元，複合年成長率為 3.52%。

脂肪萎縮症是一種代謝症候群，伴隨脂肪異常重新分佈，包括脂肪萎縮和脂肪增生。它通常是抗逆轉錄病毒療法的副作用。全球HIV感染族群的持續成長以及抗逆轉錄病毒療法（ART）計畫的顯著擴展是導致脂肪萎縮症發病率上升的主要原因，這延長了患者的平均壽命，同時也增加了他們長期承受副作用的風險。此外，臨床上需要解決與代謝異常相關的心血管風險，這也促使人們尋求超越單純美觀問題的有效管理策略。

市場概覽
預測期 2027-2031
市場規模：2025年 1.8582億美元
市場規模：2031年 2.2862億美元
複合年成長率：2026-2031年 3.52%
成長最快的細分市場 藥物治療
最大的市場 北美洲

然而，已通過核准療法的高成本和不完善的報銷體系嚴重阻礙了市場擴張，限制了中低收入地區患者的治療機會。儘管需要持續治療的人群不斷成長，但這種經濟障礙仍然是一項重大挑戰。根據聯合國愛滋病規劃署（UNAIDS）的數據，到2024年底，全球將有約3,160萬人接受抗逆轉錄病毒療法，這將顯著增加面臨治療相關脂肪代謝障礙風險的人。

市場促進因素

全球愛滋病毒感染率的上升是市場需求的根本促進因素，因為長期生存者的增加與代謝併發症發生率的增加直接相關。隨著抗逆轉錄病毒療法延長了患者的壽命，他們接受救命治療的時間也隨之延長，這累積了發生脂肪重新分佈症候群（例如脂肪萎縮和脂肪增生）的風險。不斷擴大的患者群體使得持續的醫療需求促使人們尋求干預措施來控制這些慢性副作用。根據聯合國愛滋病規劃署於2024年7月發布的《2024年概況介紹》，截至2023年，全球約有3,990萬人感染愛滋病毒，這意味著潛在的龐大病患群體需要接受治療。此外，根據美國疾病管制與預防中心（CDC）2024年的報告，到2022年底，美國預計將有120萬人感染愛滋病毒，凸顯了高價值地區市場的強勁需求。

同時，新型療法和皮膚填充劑的進步正推動收入成長，治療方案也從基礎管理發展到有效的美容和代謝修復。針對生長激素釋放因子和專用豐盈填充劑的商業化，正促使更多患者接受這些療法，以減輕與疾病相關的身體變化所帶來的社會污名。該行業展現出強勁的財務表現，顯示醫療系統和患者都願意投資於這些解決方案。例如，Theratechnologies Inc. 在 2024 年 10 月發布的「2024 年第三季財報會議紀要」中報告稱，用於減少 HIV 感染患者腹部脂肪的注射療法 EGRIFTA SV 僅在該季度就實現了 1670 萬美元的淨銷售額，這表明，儘管面臨經濟障礙，但已獲批准和核准的產品。

市場挑戰

已通過核准療法的高昂費用和不完善的報銷政策是限制全球愛滋病相關脂肪代謝障礙市場發展的主要阻礙因素。這些經濟障礙導致臨床治療需求與患者實際購買力之間存在巨大差距。由於脂肪代謝障礙的治療通常被視為次要干預措施，遠不及挽救生命的抗逆轉錄病毒療法，因此在許多地區，保險覆蓋範圍有限甚至無法覆蓋。由此，製造商難以打入中低收入市場，因為這些市場的醫療資金嚴格用於病毒抑制等基本治療，即使認證核可藥具有臨床療效，也難以廣泛應用。

鑑於全球需要長期管理的患者群體規模龐大，這種財務限制尤為嚴峻。雖然理論上市場機會巨大，但實際上，高流行地區的經濟挑戰限制了其發展，並有效限制了潛在的產生收入。根據聯合國愛滋病規劃署（UNAIDS）的數據，到2024年，全球將有約4,080萬人感染愛滋病毒。如此龐大的患者群體代表著巨大的未滿足需求，但只要高昂的自付費用和不完善的報銷體系繼續阻礙大多數感染者獲得治療，市場就無法充分利用這一需求。

市場趨勢

隨著先進的生長激素釋放因子製劑的商業化，市場格局正在重塑。這些製劑透過改進給藥系統，優先考慮提高患者的依從性。雖然傳統治療方法已證實具有臨床療效，但該產業目前正向下一代更容易使用的方案轉型，這些方案可顯著減輕長期生存者每日用藥的負擔。這項進步解決了慢性HIV治療中「治療疲勞」這一重大挑戰，並透過簡化複雜的治療方案，促進了永續的治療效果。根據Theratechnologies公司於2025年3月發布的“2025年第一季財務業績”，美國FDA核准了tesamorelin的新製劑EGRIFTA WR（F8製劑），用於治療內臟脂肪過多，這標誌著在最佳化該患者群體的長期代謝管理方面邁出了重要一步。

同時，能夠提供持久結構修復的再生生物促效劑的廣泛應用，推動了微創皮膚填充劑的普及。與傳統的透明質酸製劑不同，聚左旋乳酸等製劑透過刺激自身膠原蛋白的生成，為臉部脂肪萎縮提供了一種更持久的生理解決方案，並佔據了顯著的市場佔有率。這個細分市場已成為高德美集團核心醫美產品組合的重要收入來源，凸顯了再生醫學的商業性趨勢。根據高德美集團於2025年3月發布的2024年度報告，該公司實現了創紀錄的44.1億美元淨銷售額，其旗艦生物促效劑品牌Sculptra是注射美容領域的主要成長引擎。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

5. 全球愛滋病相關脂肪萎縮市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 按類型（藥物治療、美容矯正治療）
    • 給藥途徑（口服、注射、其他）
    • 按分銷管道（醫院藥房、零售藥房、網路藥房）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美HIV相關脂肪萎縮市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲愛滋病毒相關脂肪萎縮市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區愛滋病相關脂肪萎縮市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲愛滋病毒相關脂肪萎縮市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

10. 南美洲愛滋病毒相關脂肪萎縮市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球愛滋病相關脂肪萎縮市場：SWOT分析

第14章 波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Theratechnologies Inc
  • Amryt Pharmaceuticals, Inc.
  • Fawn Incorporation
  • Abbott Laboratories, Inc.
  • Lupin Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Bayer AG
  • Novartis Pharmaceuticals Corporation
  • AstraZeneca Plc
  • GlaxoSmithKline Plc

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 17294

The Global HIV-associated Lipodystrophy Market is projected to expand from USD 185.82 Million in 2025 to USD 228.62 Million by 2031, registering a CAGR of 3.52%. Defined as a metabolic syndrome involving abnormal fat redistribution such as lipoatrophy and lipohypertrophy, this condition frequently arises as an adverse reaction to antiretroviral regimens. Growth is primarily driven by the sustained rise in the global HIV-positive population and the extensive scale-up of antiretroviral therapy (ART) programs, which have extended patient life expectancy and increased exposure to long-term side effects. Furthermore, the clinical necessity to address cardiovascular risks linked to metabolic irregularities reinforces the demand for effective management strategies beyond mere aesthetic concerns.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 185.82 Million
Market Size 2031USD 228.62 Million
CAGR 2026-20313.52%
Fastest Growing SegmentDrug Treatment
Largest MarketNorth America

However, market expansion is significantly impeded by the high cost of approved therapeutics and insufficient reimbursement frameworks, which restrict access for patients in low-to-middle-income regions. This economic obstacle remains a critical challenge despite the growing demographic requiring continuous care. According to UNAIDS, approximately 31.6 million individuals globally were accessing antiretroviral therapy by the end of 2024, highlighting a substantial increase in the population potentially at risk of developing treatment-associated lipodystrophy.

Market Driver

The rising global prevalence of HIV infection acts as the fundamental catalyst for market demand, as an increasing number of long-term survivors correlates directly with a higher incidence of metabolic complications. With antiretroviral therapies extending lifespans, patients remain on life-saving regimens for longer periods, thereby accumulating the risk of developing adverse fat redistribution syndromes like lipoatrophy and lipohypertrophy. This expanding patient base generates a continuous medical need for interventions to manage these chronic side effects. As per the UNAIDS 'Fact Sheet 2024' released in July 2024, roughly 39.9 million people globally were living with HIV in 2023, representing a massive patient pool potentially requiring care. Additionally, the Centers for Disease Control and Prevention reported in 2024 that an estimated 1.2 million people in the United States were living with HIV at the end of 2022, highlighting significant demand in high-value regional markets.

Concurrently, advancements in novel therapeutic agents and dermal fillers are accelerating revenue growth by evolving treatment options from basic management to effective aesthetic and metabolic restoration. The commercial availability of targeted growth hormone-releasing factors and specialized volumizing fillers has encouraged adoption among patients aiming to mitigate the stigmatizing physical changes associated with the condition. This sector is demonstrating strong financial results, indicating a willingness among healthcare systems and patients to invest in these solutions. For instance, Theratechnologies Inc. reported in their 'Q3 2024 Earnings Call Transcript' from October 2024 that net sales of EGRIFTA SV, an injectable for reducing excess abdominal fat in HIV-infected patients, reached USD 16.7 million in that quarter alone, proving that efficacious, approved products drive industry expansion despite economic hurdles.

Market Challenge

The exorbitant costs of approved therapeutics combined with inadequate reimbursement policies serve as major restraints on the Global HIV-associated Lipodystrophy Market. These economic barriers create a substantial gap between the clinical necessity for treatment and the actual purchasing power of the affected population. Because lipodystrophy management is frequently classified as a secondary intervention relative to life-saving antiretroviral therapy, insurance coverage is often restricted or unavailable in many jurisdictions. As a result, manufacturers struggle to penetrate low-to-middle-income markets where healthcare funds are rigorously allocated toward essential viral suppression, hindering the widespread uptake of approved drugs despite their clinical effectiveness.

This financial constraint is particularly acute given the immense scale of the global patient population requiring long-term management. While the market opportunity is theoretically extensive, it is practically limited by affordability challenges in high-burden regions, effectively capping potential revenue generation. According to UNAIDS, there were approximately 40.8 million people living with HIV worldwide in 2024. This vast patient base represents a significant unmet need, yet the market is unable to fully capitalize on this demand as long as high out-of-pocket costs and reimbursement deficiencies make treatments inaccessible for the majority of individuals living with the condition.

Market Trends

The market landscape is being reshaped by the commercialization of advanced growth hormone-releasing factor formulations that prioritize patient adherence through improved delivery systems. Although earlier therapies demonstrated clinical efficacy, the industry is now shifting toward next-generation, user-friendly options that significantly alleviate the logistical burden of daily administration for long-term survivors. This progression tackles the critical challenge of "treatment fatigue" in chronic HIV care, promoting sustained therapeutic outcomes by simplifying complex regimens. According to the 'First Quarter 2025 Financial Results' from Theratechnologies Inc. in March 2025, the U.S. FDA approved EGRIFTA WR, a new F8 formulation of tesamorelin designed to treat excess visceral abdominal fat, marking a significant step forward in optimizing long-term metabolic management for this patient group.

Simultaneously, the rising adoption of minimally invasive dermal fillers is being driven by a surge in regenerative biostimulators that provide durable structural restoration surpassing transient volume correction. Unlike traditional hyaluronic acid alternatives, agents such as poly-L-lactic acid are securing substantial market share by stimulating the host's own collagen production, offering a more permanent physiological solution for facial lipoatrophy. This sub-segment has become a crucial revenue driver for major aesthetic portfolios, confirming the commercial trend toward regenerative medicine. As noted in the 'Annual Report 2024' by Galderma Group AG in March 2025, the company achieved record net sales of USD 4.41 billion, with its flagship biostimulator brand Sculptra acting as a primary growth engine within the injectable aesthetics category.

Key Market Players

  • Theratechnologies Inc
  • Amryt Pharmaceuticals, Inc.
  • Fawn Incorporation
  • Abbott Laboratories, Inc.
  • Lupin Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Bayer AG
  • Novartis Pharmaceuticals Corporation
  • AstraZeneca Plc
  • GlaxoSmithKline Plc

Report Scope

In this report, the Global HIV-associated Lipodystrophy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

HIV-associated Lipodystrophy Market, By Type

  • Drug Treatment
  • Cosmetic Corrective Treatment

HIV-associated Lipodystrophy Market, By Route of Administration

  • Oral
  • Injectables
  • Others

HIV-associated Lipodystrophy Market, By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

HIV-associated Lipodystrophy Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global HIV-associated Lipodystrophy Market.

Available Customizations:

Global HIV-associated Lipodystrophy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global HIV-associated Lipodystrophy Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Drug Treatment, Cosmetic Corrective Treatment)
    • 5.2.2. By Route of Administration (Oral, Injectables, Others)
    • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America HIV-associated Lipodystrophy Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Route of Administration
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States HIV-associated Lipodystrophy Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Route of Administration
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Canada HIV-associated Lipodystrophy Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Route of Administration
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Mexico HIV-associated Lipodystrophy Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Route of Administration
        • 6.3.3.2.3. By Distribution Channel

7. Europe HIV-associated Lipodystrophy Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Route of Administration
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany HIV-associated Lipodystrophy Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Route of Administration
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. France HIV-associated Lipodystrophy Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Route of Administration
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. United Kingdom HIV-associated Lipodystrophy Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Route of Administration
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. Italy HIV-associated Lipodystrophy Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Route of Administration
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain HIV-associated Lipodystrophy Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Route of Administration
        • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific HIV-associated Lipodystrophy Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Route of Administration
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China HIV-associated Lipodystrophy Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Route of Administration
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. India HIV-associated Lipodystrophy Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Route of Administration
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Japan HIV-associated Lipodystrophy Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Route of Administration
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. South Korea HIV-associated Lipodystrophy Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Route of Administration
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Australia HIV-associated Lipodystrophy Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Route of Administration
        • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa HIV-associated Lipodystrophy Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Route of Administration
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia HIV-associated Lipodystrophy Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Route of Administration
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. UAE HIV-associated Lipodystrophy Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Route of Administration
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. South Africa HIV-associated Lipodystrophy Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Route of Administration
        • 9.3.3.2.3. By Distribution Channel

10. South America HIV-associated Lipodystrophy Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Route of Administration
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil HIV-associated Lipodystrophy Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Route of Administration
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Colombia HIV-associated Lipodystrophy Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Route of Administration
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. Argentina HIV-associated Lipodystrophy Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Route of Administration
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global HIV-associated Lipodystrophy Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Theratechnologies Inc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Amryt Pharmaceuticals, Inc.
  • 15.3. Fawn Incorporation
  • 15.4. Abbott Laboratories, Inc.
  • 15.5. Lupin Pharmaceuticals, Inc.
  • 15.6. Pfizer Inc.
  • 15.7. Bayer AG
  • 15.8. Novartis Pharmaceuticals Corporation
  • 15.9. AstraZeneca Plc
  • 15.10. GlaxoSmithKline Plc

16. Strategic Recommendations

17. About Us & Disclaimer